Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lots of crimes
1. corporate embezzlement by management
2. misleading investors with false FDA approval
3. insurance scam, buys insurance and commmiting investor fraud
4. fake creditor claim submission deliberately signging contracts knowing it cannot commit ausin breach of contract lawsuit.
5. stock manipulatoin of the market makers.
this bankruptcy was a fraud. to clean the hands of the shorts who shorted the sharees in 2021 and transfer the assets which was the ip of lenz and close this stock scam and walk free and no jail with assistance from the gov't and cops(SEC) as for retail investors who go robbed, you won't get dime of that 3 million dollar settlement, that was an insurances scam too. 5 million had to paid out because the company paid $250,000/annual premium in insurance policy for lawsuits of managemennt corruption.
why spends millions to declare bankruptcy?
I hope the public is not pay for the Judge time wasting his time in this bogus court case.
even the trading is scam..AI front run humans and manipulate human traders. entire operation is like watching WWF wrestling match all this drama about bankruptcy .lawsuits. FDA approval, it's was a an act an fake. they want to go bankrupt with fake lawsuits and management deliberately sabotage the company with misconducts like embezzlment to cause a bankruptcy. this company only 5 million in debt in 2022 even if FDA didn't approve there was little chance of bankrupty as it had over 5 million in cash in 2022 and management could easily raise investment in 2021 or 2022 and raise more capital with share issuance when equity was still hot..but it's 2024 nobody wants to ivnest in money losing drug companies or vaccines anymore. SPAC ipo is dead. why reddit ddin't ipo in 2021 is beyond me, right now the market for equities dried up zero bid and even trading is dead, not even a dead cat bounce now.
as for this stock scam, it's gov't assisted robbery of public investors money. technically it's not illegal. but immoral but plan was to rip of investors from the beginning. from ipo like hundreds of these stocks and things like crypto. false hope and fomo etc when it was shell game. stock picking is scam. you are to choose 1 stock from 10 stock...all 10 stocks are scam. or shell game.no winners in all 10 stocks you were told to pick. investment fraud is what it is.
the latest scam is crypto ETF. when crypto classic pyramid scheme MLM scheme. collapses Cryto ETF and itself is MLM scam very similiar.
this stock is classic stock scam. wasting the courts time and SEC time etc. watching this case and this company is like watching WWF wrestling ...fake show. fake investment fraud. there was no investment opportunity. they took your money and not returning. by bankrupting the company with creating lawsuits and deliberately sabotaging the business with management misconduct. and yet nobody goes to jail everybody makes money except the ipo institutional investors who were bribed to buy these shares with other people's money and a few retail speculators. it was all a stock scam like many of the SPAC which ipo in 2021. Reddit waited too long why it didn't rush to ipo in 2021 when even a picture was bided on.
What plan? it's already bankrupt. no plan. but wait for death.
there is nothing to liquidate.
Why would you need creditor permission? if it wasn't for the bogus 27 million lawsuit, and bogus 3 million lawsuit humanigen would have gotten financing and no need to file chapter 11 to get the lawsuits off their back as that was what prevented and investment from new shareholders if it was not for the breach of contract lawsuits and self sabotaging by manageent to get the lawsuits this company could easily solicit investment banking or investments in 2022..it's 2024 and much harder to get any investment but that was part of the stock scam. The money was already made when it ipo and ripped off 160 million from ipo investors. when liquidity was a high. now these same companies if they were to ipo they won't get fraction of what they raised in 2021. many companies are not even ipo as no investors interest. in non=profit equities.
COMBINED CHAPTER 11 PLAN OF LIQUIDATION
AND DISCLOSURE STATEMENT FOR HUMANIGEN, INC
what is this? it's look like chapter 7. and dissolution of the company???
the company is worth only $100 cheaper than delaware incorporation.
will the company still trade as shell company?
I believe Jay lives near Ft Worth, which has the big stockyards.
Jay is cowtown for south jersey cowtown?
Welcome to the room, oldstocks, and thank you for your post.
I had stock in Planet Hollywood back in 1999/2000
On October 12, 1999, the company filed for Chapter 11 bankruptcy in an attempt to reorganize. They closed or sold poorly performing Planet Hollywood restaurants and Official All Star Cafes. It moved to focus to its original theme concept, stopping operation of Planet Movies by AMC and sold its Sound Republic units.
But shareholders got nothing
https://www.gainesville.com/story/news/2002/12/17/planet-hollywood-emerges-from-bankruptcy-again/31622270007/
Everything depends on how much the company paid for the assets in the sales.
Stockholders are the last ones to be paid after all debts are paid.
If all debts are paid can the remaining of what is left become a shell company and still trade or will all shares be canceled.
For shareholders at this point what do you have to lose by waiting to figure it out.
I hope the company was sold in a bidding war and i hope all shareholders get something
I can't say that you ARE reading it wrong, sosjtb.
"As soon as practicable after payment in full of, or reserve for, all other Allowed Claims, the Liquidating Trust shall
pay to each holder of an Allowed Subordinated Claim or an Allowed Existing Equity Interest its pro rata share of any
remaining amounts in the Liquidating Trust subject to the terms and conditions of this Combined Plan and Disclosure
Statement, the Liquidating Trust Agreement, and the Bankruptcy Code. No distribution to Class 4 (Subordinated
Claims) or Class 5 (Existing Equity Interests) is anticipated."
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1074462&projectCode=HUM&docketNumber=226&source=DM
p 33/65
But, you certainly COULD BE reading it wrong.
"As soon as practicable after payment in full of, or reserve for, all other Allowed Claims, the Liquidating Trust shall
pay to each holder of an Allowed Subordinated Claim or an Allowed Existing Equity Interest its pro rata share of any
remaining amounts in the Liquidating Trust subject to the terms and conditions of this Combined Plan and Disclosure
Statement, the Liquidating Trust Agreement, and the Bankruptcy Code. No distribution to Class 4 (Subordinated
Claims) or Class 5 (Existing Equity Interests) is anticipated...
there is no assurance that the Liquidating Trust will be successful in prosecuting any Cause of Action or generate sufficient
proceeds from the Causes of Action for Distribution. "
p 33/65 p 35/65
The case remains a CH11, and the recall of the loaned shares, especially if Novavax purchases the lenz/vaccine cocktail, or we combine/partner/merge through Taran into Sanofi, and get regulatory approval from Australia, perhaps with a PRV, we could easily see Ed Dowd announce a target price of $67 for our shares.
It’s over Jay, the plan of liquidation appears to show no recovery for shareholders and HGEN stock will be canceled in May…unless I’m reading that wrong?
"The new Humanigen may be stronger than I expected."
At one point, I actually questioned why the CH11 bankruptcy would be necessary. If Humanigen owns 110M of the 119M shares they have issued, and if our float of 229M shares is 192% of our OS, that could only mean that Humanigen has loaned the excess shares in our market. If so, Humanigen would be positioned to issue a recall of their loaned shares, and cause an even more massive short squeeze than they did as Kalobios.
I see no change in those circumstances.
I think Humanigen has held off recalling their loaned shares, until news, such as in regards to regulatory approval or authorization of lenzilumab, or news regarding a business combination/merger/partnership, was ready to be announced. This extended delay caused the financial constraints that forced the CH11 (as the US regulators tried to force us out of business, and protect their financial investment in Moderna, and promote their mRNA ideology, in my opinion).
I really think that Novavax may have used lenz as an enhancement in their prototype vaccine. I also think that Sanofi graduated, as Gracell did, from Humanigen's incubation of their their products, used with lenz for enhanced safety and efficacy. And I note how this CH11 is nearing completion as Sanofi prepares to spin-off their healthcare division, and the PREACH-M trial results are placed for regulatory approval in Australia, perhaps with a Priority Review Voucher worth ~$100M.
The only things that have changed are:
We may have partnership interests from Novavax, PREACH-M (and/or Sanofi), and Gracell (and perhaps AstraZeneca), exerting authorization approval of lenz from Regulators (probably overseas).
We have no secured debt obligations.
We have non-debtor Humanigen subsidiaries prepared for possible merger use in the UK, Australia, and the Republic of Ireland.
And we have shocking safety and efficacy failures, to include vaccine injuries and excess deaths, caused by the standard of care currently in use.
I'm very optimistic, and I believe that Humanigen has never been stronger than we are now.
Chapter 11 Plan of Liquidation filed with the court. Docket 226
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1074462&projectCode=HUM&docketNumber=226&source=DM
First of all, thank you for sharing that link, GURUBK. I'd certainly like to see our equity tied again to the IP rights, even if just by exclusive license. But I just don't think that this is going to happen solely by acquisition. Fine with me, if it does. The new Humanigen may be stronger than I expected. I just thought, and still think, that we'll see a merger, business combination, or partnerships factor into our new course, as well.
I'm interpreting an entirely different vibe, dlog. It seems that antibodies derived from vaccine-induced infection are weakening, and at the same time, the virulence of the next coronavirus to circulate, will be significantly worse than any strain or type that we have seen so far.
If so, then most of the covid that lenz will have to fight will be vaccine-induced, AND more deadly, unless the FDA prohibits mRNA vaccines, and authorizes lenz, before the next variant begins to circulate. I am very curious to see if lenz will be capable of restoring the the immune response in this scenario.
I hope you are right.
So, this means our stock is going to be brought back from the Dead the way I am interpreting this?
This could go multi-dollars once they file, and we go pink current. WOW!!!
Anybody holding shares here are sitting on a Goldmine!
Any thoughts on Humanigen being acquired by Taran?
i just spoke to a patient who was a nurse in the NIH for 30 years. cancer section , we were discussing immunomodulators, and how they are being used to treat cancer, and she blurts out , we had those thirty years ago… so i ask why are they only being used now , and she says i dont know…
so at the rate those clowns move, lenzilumab might be approved 2045
I think it would be naive to think that Moderna, with the $2.5B US government investment in their company, has (..."nothing to do with our company"). The US government, in my opinion, is keeping lenz out of the covid market, to safeguard their Moderna investment, and misplaced faith in mRNA technology.
There's a reason the charges the UK wants to file regarding the forced acceptance of mRNA vaccines, include charges of murder. I hope TX AG Ken Paxton also files criminal charges against Pfizer, Moderna, Lancet, Thorax, NIAID, the NIH, the CDC, and the FDA.
Again, nothing to do with our company. I suggest you dig into Epiq Corporate restructuring, as this apparently is the company being used during chapter 11
Easy come, easy go.
"Moderna has scored $2.48 billion in R&D and supply funding from the U.S. government for its program."
https://www.fiercepharma.com/pharma/after-nearly-1b-research-funding-moderna-takes-1-5b-coronavirus-vaccine-order-from-u-s
"Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges
PUBLISHED THU, APR 11 2024...
The biotech company said it has not received any vaccine orders for Africa since 2022 and has taken more than $1 billion in losses and write-downs related to the cancellation of previous orders from the continent.
https://www.cnbc.com/2024/04/11/moderna-halts-kenya-vaccine-plant-plans-as-covid-shot-demand-plunges.html
The lack of demand for mRNA covid vaccines in Africa is noteworthy.
"This study shows that the highest number of cases per million population was recorded in Europe, while the trend of new cases is lowest in Africa. The mortality rates in different continents were as follows: North America 4.57%, Europe 3.74%, South America 3.87%, Africa 3.49%, Oceania and Asia less than 2%."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157209/#:~:text=Results%3A%20This%20study%20shows%20that,cases%20is%20lowest%20in%20Africa.
It's frustrating to me, as a US citizen, to see our tax dollars squandered in support of deadly mRNA vaccine development. It's even more frustrating to me, as a US investor in Humanigen, to see Lenzilumab side-lined from the opportunity of being used as a covid traditional-vaccine-enhancement and therapeutic treatment, despite Lenzilumab's superior safety and efficacy peer-reviewed trial results.
I was glad to hear Dr. Kelly Victory interview Ed Dowd recently. Ed is a former portfolio manager at Blackrock, and I believe they may still maintain a position with Humanigen.
I've come to enjoy reading clinical trial reviews, and following the logic the trial investigators use in writing their findings. But Ed opened a new perspective on the logic he uses to make investment decisions, such as in biotech (continuing with Humanigen)? I like the way in which Ed explained his estimation of excess deaths, which brought a sharp focus on the astounding increase in excess deaths in the younger population. And another thing I really like is that he didn't just focus on covid. He noted the developments in neurological and cancer indications, as well.
I think lenz has tremendous opportunities in preventing and/or treating all three indications. I've been saying that for several years. And I really appreciated hearing a financial guy express his conclusions in this regard.
I know it will be back down tomorrow, but it sure looks nice seeing this up 89,900%
I Can't wait until we achieve these gains for real when it gets re-listed on the OTC.
.01 to Dollars will make an awesome retirement party for me!
Regarding Dr. McCullough's congressional testimony about a lack of recommended covid treatment protocols, we know that in 2021, the NIH did recognize the substantial improvement lenzilumab demonstrated in treating hospitalized covid patients.
""Preliminary data from a double-blind, placebo-controlled randomized trial of lenzilumab did show a significant improvement in the primary endpoint of ventilator-free survival through Day 28 among those who received the GM-CSF inhibitor."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165682015
Since then, and as now, there has been no justification for the US and UK Regulators to negligently permit thousands of preventable deaths every week. Those deaths should be added to the number of "excess deaths" due to the mRNA vaccines, because keeping lenz off the market is only to protect the covid profits from the Pfizer and Moderna mRNA vaccines (and the financial investments in those companies made by the US and German governments).
"Sanofi needs to spin-off their healthcare sector, and we saw the S-8 regarding the Securities to be offered to employees in employee benefit plans filed today."
Other Sanofi news hitting the wire today was in regards to their on-going trial to treat Parkinson's Disease.
"A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the New England Journal of Medicine reported on Thursday."
https://www.morningstar.com/news/marketwatch/20240404312/diabetes-medication-appears-to-slow-progress-of-parkinsons-disease-in-french-backed-trial
Loss of motor control completely changes the quality of life for affected patients. I hope lenz may have a role in improving the efficacy of Sanofi's lixisenatide.
Humanigen has never been stronger that we are now. And the world will be a better place as we step into our rightful covid and oncology positions.
If, by some miracle, certain of the conclusions I have drawn develop as I surmised, then the counter-parties to those events need to complete their tasks, in addition to Humanigen doing the same. Baudax needs to complete their CH11, and hopefully sell Tera-Immune to us. Novavax may need to get additional regulatory approval or authorization to use lenz as their prototype vaccine enhancement. Sanofi needs to spin-off their healthcare sector, and we saw the S-8 regarding the Securities to be offered to employees in employee benefit plans filed today.
Humanigen has never been stronger that we are now. And the world will be a better place as we step into our rightful covid and oncology positions.
With all of HGEN/Lenz exposure overseas you would think overseas traders who can still buy shares here would be buying them up. I have seen other EM tickers trading much higher on the EM based on rumors and speculation of a reverse merger.
GVSI with 2.2 billion shares outstanding was trading at .05 based on reverse merger rumors while on the EM.
If there was anything here, overseas investors/traders would be buying…they aren’t. That a big sign we are done IMO.
Doesn’t mean it’s worthless though.., someone in the coming years will probably want the shell…who knows.
I don’t think Durrant is going to go after the hedge funds who shorted since he may need them in the future and that’s just the way the game is played. Hedge funds will always win at the expense of shareholders.
Why isn't management providing any insight then, as to the plan forward? Not a peep, nothing for shareholders.
And no CH7. So the bankruptcy court judge does not agree with your assessment of Humanigen's prospects and future. The company is restructuring, under CH11. Give it a minute.
Sanofi filed an S-8 securities Registration Statement today. I think Sanofi may be our most-tenured shareholder, and that their oncology market could be enhanced by lenzilumab, such as we have seen in CMML. Sanofi previously announced plans to spin-off their healthcare sector, and I am excited about the partnership opportunity this could provide to Humanigen/Taran.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524086673/d803515ds8.htm
The filing notes that, "The information required by Item 1 and Item 2 of Part I of Form S-8 is omitted from this filing..."
The type of information withheld, if I am reading the prospectus instructions correctly, can be found on pages 5-7 in the following link.
https://www.sec.gov/files/forms-8.pdf
You don't seem to grasp it, the company is done, no website, no product.
You're missing the point I was making, which is that worldwide, the majority of the covid vaccines are non-mRNA-based, and I think they represent a large market for our patented method of vaccine enhancement. There is nothing "off-topic" about that, even if some staff of government agencies, such as NIH or USAMRIID, continue to promote mRNA vaccines, which pose increased risk of deadly consequences, not only to this generation, but to the unborn of the next, as well.
Applicant:Humanigen
Owned by: Taran
"What do these companies have to do with HGEN?"
Most vaccine manufacturers don't use mRNA technology, they use traditional methodology, and incorporate an inactive form of the virus, for example. That's what Novavax does, and they are the only non-mRNA vaccine manufacturer authorized in the US.
The majority of the overseas vaccine manufacturers should be candidates to use lenz as an enhancement to their vaccines. We patented the process for this application, as I've shown before.
"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPELL"
https://patents.justia.com/assignee/humanigen-inc
It is not accurate to consider the subject of vaccine enhancement as "off topic." Quite the contrary, vaccine enhancement is THE MAIN OPPORTUNITY I am hoping to see Humanigen capture.
...Come on man, The webpage is gone. The product is gone. Management is gone.
The only argument the antagonists have is always centered around the fact that none of the developments I fully expect to see realized have, as yet, come to pass. Instead, there is, "Not a peep from management."
I haven't seen anything disproven that was in the Top Line Data of the LIVE-AIR trial. Not only were those trial results verified by the Lancet peer-review, they were bolstered by the Thorax peer-review, based upon patient stratification by CRP levels.
I would link, for the 100th time, Humanigen's home page, with access to the Lancet and Thorax peer reviews, but I am now getting an error message trying to do so.
"Looks like this domain isn't
connected to a website yet"
https://www.humanigen.com/
All the tabs associated with the home page are accessible (Other, News, Events, etc).
https://ir.humanigen.com/English/news/default.aspx
I wonder if the Home page is getting a facelift.
What do these companies have to do with HGEN? Was there a PR I missed about a partnership? It's over pack it up. Not a peep from management.
Followers
|
327
|
Posters
|
|
Posts (Today)
|
7
|
Posts (Total)
|
43266
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |